Status:
COMPLETED
Epoprostenol for Injection in Patients With Pulmonary Arterial Hypertension
Lead Sponsor:
Actelion
Collaborating Sponsors:
Chiltern International Ltd.
Effi-Stat
Conditions:
Pulmonary Arterial Hypertension
Eligibility:
All Genders
Phase:
PHASE3
Brief Summary
This is an open-label, nonrandomized extension to study AC-066A301. The study will assess safety and tolerability of ACT-385781A while providing a means for continuing treatment after ending participa...
Eligibility Criteria
Inclusion
- Signed informed consent prior to initiation of any study-mandated procedure
- Patients who completed participation in study AC-066A301
- Patients who have not obtained access for commercial EFI at the time of ending participation in study AC-066A301
Exclusion
- Patients who prematurely discontinued study drug in study AC-066A301
- Patients for whom continued treatment with EFI is no longer considered appropriate
Key Trial Info
Start Date :
June 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2015
Estimated Enrollment :
41 Patients enrolled
Trial Details
Trial ID
NCT01470144
Start Date
June 1 2011
End Date
July 1 2015
Last Update
February 4 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.